Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions
Completed
Novartis Pharmaceuticals
Phase 4
2002-05-01
It is the aim of this multicentric clinical study to assess the efficacy and tolerability of
zoledronic acid in combination with radiotherapy in patients with advanced osteolytic bone
lesions in terms of the reduction of pain and analgesic consumption.
Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
Completed
National Cancer Institute (NCI)
Phase 2
2005-11-28
This randomized phase II trial is studying zoledronate to see how well it works compared to
observation in maintaining bone mineral density in patients who are undergoing surgery to
remove both ovaries. Zoledronate may prevent bone loss in patients who are undergoing surgery
to remove the ovaries.
Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
Completed
Gynecologic Oncology Group
Phase 2
2005-11-28
This randomized phase II trial is studying zoledronate to see how well it works compared to
observation in maintaining bone mineral density in patients who are undergoing surgery to
remove both ovaries. Zoledronate may prevent bone loss in patients who are undergoing surgery
to remove the ovaries.
Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis
Completed
Novartis Pharmaceuticals
Phase 3
2006-12-01
This study will investigate if the drug zoledronic acid given once yearly is safe and has
beneficial effects in treating osteoporosis by reducing bone loss and fractures in men with
osteoporosis.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
